{'fraction_non_alphanumeric': 0.033707865168539325, 'fraction_numerical': 0.008739076154806492, 'mean_word_length': 6.290909090909091, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial

Background  Melasma is a hyperpigmentation disorder predominantly affecting sun‐exposed areas in women, which is often refractory to treatment. Most commercially available treatments incorporate inhibitors of tyrosinase, a key enzyme in melanin production within the melanocyte. In general, however, the efficacy of these therapies is somewhat limited. Recent studies have identified other enzymes that play an important role in melanogenesis, including tyrosinase‐related protein‐1 (TRP‐1), which catalyses the oxidation of the melanogenetic intermediate 5,6‐dihydroxyindole‐2‐carbolylic acid. Rucinol (4‐n‐butylresorcinol) has been shown to inhibit the activity of both tyrosinase and TRP‐1.